S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.64 (+0.38%)
AAPL   190.93 (+0.60%)
MSFT   382.79 (+1.10%)
META   336.32 (+0.48%)
GOOGL   136.71 (+0.22%)
AMZN   147.54 (-0.13%)
TSLA   242.20 (+2.59%)
NVDA   481.10 (-0.27%)
NIO   7.26 (+0.97%)
BABA   76.08 (-1.87%)
AMD   122.47 (-0.15%)
T   16.16 (-0.31%)
F   10.40 (+0.58%)
MU   75.66 (-2.39%)
CGC   0.54 (-1.96%)
GE   119.74 (-0.19%)
DIS   94.14 (-1.08%)
AMC   6.66 (-2.06%)
PFE   29.98 (-0.53%)
PYPL   57.27 (+1.56%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.64 (+0.38%)
AAPL   190.93 (+0.60%)
MSFT   382.79 (+1.10%)
META   336.32 (+0.48%)
GOOGL   136.71 (+0.22%)
AMZN   147.54 (-0.13%)
TSLA   242.20 (+2.59%)
NVDA   481.10 (-0.27%)
NIO   7.26 (+0.97%)
BABA   76.08 (-1.87%)
AMD   122.47 (-0.15%)
T   16.16 (-0.31%)
F   10.40 (+0.58%)
MU   75.66 (-2.39%)
CGC   0.54 (-1.96%)
GE   119.74 (-0.19%)
DIS   94.14 (-1.08%)
AMC   6.66 (-2.06%)
PFE   29.98 (-0.53%)
PYPL   57.27 (+1.56%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.64 (+0.38%)
AAPL   190.93 (+0.60%)
MSFT   382.79 (+1.10%)
META   336.32 (+0.48%)
GOOGL   136.71 (+0.22%)
AMZN   147.54 (-0.13%)
TSLA   242.20 (+2.59%)
NVDA   481.10 (-0.27%)
NIO   7.26 (+0.97%)
BABA   76.08 (-1.87%)
AMD   122.47 (-0.15%)
T   16.16 (-0.31%)
F   10.40 (+0.58%)
MU   75.66 (-2.39%)
CGC   0.54 (-1.96%)
GE   119.74 (-0.19%)
DIS   94.14 (-1.08%)
AMC   6.66 (-2.06%)
PFE   29.98 (-0.53%)
PYPL   57.27 (+1.56%)
XOM   104.77 (+0.78%)
S&P 500   4,565.81 (+0.34%)
DOW   35,511.10 (+0.50%)
QQQ   390.64 (+0.38%)
AAPL   190.93 (+0.60%)
MSFT   382.79 (+1.10%)
META   336.32 (+0.48%)
GOOGL   136.71 (+0.22%)
AMZN   147.54 (-0.13%)
TSLA   242.20 (+2.59%)
NVDA   481.10 (-0.27%)
NIO   7.26 (+0.97%)
BABA   76.08 (-1.87%)
AMD   122.47 (-0.15%)
T   16.16 (-0.31%)
F   10.40 (+0.58%)
MU   75.66 (-2.39%)
CGC   0.54 (-1.96%)
GE   119.74 (-0.19%)
DIS   94.14 (-1.08%)
AMC   6.66 (-2.06%)
PFE   29.98 (-0.53%)
PYPL   57.27 (+1.56%)
XOM   104.77 (+0.78%)

Zura Bio (ZURA) Competitors

$4.75
+0.28 (+6.26%)
(As of 11:47 AM ET)
Compare
Today's Range
$4.53
$4.75
50-Day Range
$4.00
$7.00
52-Week Range
$3.91
$37.55
Volume
42,732 shs
Average Volume
320,687 shs
Market Capitalization
$204.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.60

ZURA vs. MESO, TCRX, ALVR, ERYP, CMPX, HARP, STRO, IVVD, GNFT, and CLLS

Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Mesoblast (MESO), TScan Therapeutics (TCRX), AlloVir (ALVR), ERYTECH Pharma (ERYP), Compass Therapeutics (CMPX), Harpoon Therapeutics (HARP), Sutro Biopharma (STRO), Invivyd (IVVD), Genfit (GNFT), and Cellectis (CLLS). These companies are all part of the "biological products, except diagnostic" industry.

Zura Bio vs.

Mesoblast (NASDAQ:MESO) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Mesoblast received 393 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 71.23% of users gave Mesoblast an outperform vote.

CompanyUnderperformOutperform
MesoblastOutperform Votes
401
71.23%
Underperform Votes
162
28.77%
Zura BioOutperform Votes
8
100.00%
Underperform Votes
No Votes

2.6% of Mesoblast shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 15.8% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Mesoblast presently has a consensus target price of $7.13, suggesting a potential upside of 393.08%. Zura Bio has a consensus target price of $16.60, suggesting a potential upside of 265.64%. Given Zura Bio's higher possible upside, equities analysts clearly believe Mesoblast is more favorable than Zura Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mesoblast
1 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.17
Zura Bio
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
3.20

Zura Bio has lower revenue, but higher earnings than Mesoblast.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mesoblast$7.50M31.05-$81.89M-$0.56-2.55
Zura BioN/AN/A$3.55MN/AN/A

Mesoblast has a beta of 3.39, meaning that its share price is 239% more volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.

Zura Bio has a net margin of 0.00% compared to Zura Bio's net margin of -1,061.43%. Zura Bio's return on equity of -16.32% beat Mesoblast's return on equity.

Company Net Margins Return on Equity Return on Assets
Mesoblast-1,061.43% -16.32% -12.26%
Zura Bio N/A -74.71%-38.33%

In the previous week, Mesoblast had 4 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Mesoblast and 1 mentions for Zura Bio. Mesoblast's average media sentiment score of 1.35 beat Zura Bio's score of -0.45 indicating that Zura Bio is being referred to more favorably in the news media.

Company Overall Sentiment
Mesoblast Neutral
Zura Bio Positive

Summary

Mesoblast beats Zura Bio on 9 of the 16 factors compared between the two stocks.


Get Zura Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZURA vs. The Competition

MetricZura BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$204.68M$2.51B$4.47B$6.68B
Dividend YieldN/A2.37%2.96%20.20%
P/E RatioN/A3.6398.4211.10
Price / SalesN/A197.382,513.5057.81
Price / Cash4.3623.4221.4722.84
Price / Book-2.153.173.794.49
Net Income$3.55M$54.90M$121.28M$175.83M
7 Day Performance6.50%1.15%2.76%2.14%
1 Month Performance-4.04%12.29%13.10%9.46%
1 Year PerformanceN/A2.72%4.79%2.51%

Zura Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MESO
Mesoblast
1.8887 of 5 stars
$1.21
+4.3%
$7.13
+488.8%
-58.9%$197.04M$7.50M-2.1683Gap Up
TCRX
TScan Therapeutics
2.3483 of 5 stars
$4.18
-9.3%
$11.50
+175.1%
+120.4%$199.91M$16.93M-1.70145News Coverage
ALVR
AlloVir
1.9165 of 5 stars
$1.56
-4.9%
$18.75
+1,101.9%
-79.0%$177.94MN/A-0.93114
ERYP
ERYTECH Pharma
0 of 5 stars
$4.97
+6.9%
N/A+685.4%$169.58M$32.66M0.0049Gap Up
CMPX
Compass Therapeutics
1.9321 of 5 stars
$1.69
flat
$9.33
+451.8%
-62.5%$215.45MN/A-5.1226
HARP
Harpoon Therapeutics
2.2492 of 5 stars
$12.99
+1.4%
$29.50
+127.1%
+41.8%$219.95M$37.34M-1.4850Gap Down
High Trading Volume
STRO
Sutro Biopharma
2.7628 of 5 stars
$2.69
-2.9%
$14.00
+420.4%
-69.3%$163.96M$48.64M-0.92298Positive News
Gap Up
IVVD
Invivyd
1.7636 of 5 stars
$1.47
-2.0%
$3.00
+104.1%
-29.9%$161.87MN/A-0.9584Gap Down
GNFT
Genfit
2.0012 of 5 stars
$3.19
-3.3%
$7.50
+135.1%
-15.0%$158.97M$20.40M0.00154
CLLS
Cellectis
1.9043 of 5 stars
$2.84
-8.4%
$9.75
+243.3%
+21.7%$157.86M$16.50M-1.70231Gap Up

Related Companies and Tools

This page (NASDAQ:ZURA) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -